Litigation Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
✉ Email this page to a colleague
CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-03-15 |
| Court | District Court, D. New Jersey | Date Terminated | 2023-12-29 |
| Cause | 15:1126 Patent Infringement | Assigned To | Renee Marie Bumb |
| Jury Demand | None | Referred To | Leda Dunn Wettre |
| Parties | TEVA PHARMACEUTICALS USA, INC. | ||
| Patents | 10,166,242; 10,166,243; 10,195,214; 10,500,216; 8,921,348; 9,829,495; 9,943,526 | ||
| Attorneys | LAUREN RUTH MALAKOFF | ||
| Firms | Quinn Emanuel Urquhart & Sullivan, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for CORCEPT THERAPEUTICS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-07-06 | 15 | of United States Patent Nos. 8,921,348 (“’348 patent”), 9,829,495 (“’495 patent”), and 9,943,526 … States Patent (10) Patent No.: US 8,921,348 B2 … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 44. … 300 mg, before the expiration of U.S. Patent Nos. 8,921,348 and 9,829,495....” 52. … US 8,921,348 B2 1 | External link to document | |
| 2021-05-26 | 202 | Summary Judgment of Infringement of U.S. Patent No. 10,195,214 (Attachments: # 1 Statement in Response … 15 March 2018 1:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2023-04-21 | 238 | Letter | drug-drug interaction patents (U.S. Patent No. 10,195,214 (“the ’214 patent”) and U.S. Patent No. 10,842,800…interaction patents (the ’214 patent and the ’800 patent) and the food-effect patents (U.S. Patent No. 10,…10,500,216 (“the ’216 patent”) and U.S. Patent No. 10,842,801 (“the ’801 patent”)), Teva admits that the…Teva that the two patents in the 23-1505 action are closely related to the patents in the 18-3632 action…to unadjudicated patent claims where “the differences between the unadjudicated patent claims and adjudicated | External link to document |
| 2023-05-15 | 243 | Stipulation and Order AND ~Util - Set Deadlines/Hearings | U.S. Patent No. 10,166,242 (“the ’242 patent”), U.S. Patent No. 10,166,243 (“the ’243 patent”), and… U.S. Patent No. 8,921,348 (“the ’348 patent”) and U.S. Patent No. 9,829,495 (“the ’495 patent”) by …U.S. Patent No. 10,842,800 (“the ’800 patent”) and U.S. Patent No. 10,842,801 (“the ’801 patent”); …allegations of infringement of U.S. Patent No. 9,943,526 (“the ’526 patent”); WHEREAS, on February…and U.S. Patent No. 10,195,214 (“the ’214 patent”); WHEREAS, on February 21, 2019, C.A. Nos | External link to document |
| 2023-08-11 | 260 | Notice (Other) | reference each patent or publication listed on the face of U.S. Patent Nos. 10,195,214, 10,500,216, 10,842,800… a. The inventors identified in U.S. Patent Nos. 10,195,214, 10,500,216, 10,824,800, and… Name of Patentee USA 10,195,214 02/05/2019 Joseph K. Belanoff …particular patent or publication is not an admission or representation that reliance upon such patent or publication… I. Patents and Publications: PATENTS Country | External link to document |
| 2023-09-01 | 266 | Stipulation and Order | brought claims of patent infringement of United States Patent Nos. 8,921,348 (“the ’348 patent”), 9,829,495… t t t 3 t t t ’495 patent; WHEREAS, on August 17, 2023, Corcept… u st t t t ’801 patent; … 29 December 2023 1:18-cv-03632 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
